Home > Healthcare > Pharmaceuticals > Finished Drug Form > Organ Transplant Rejection Medication Market

Organ Transplant Rejection Medication Market Share

Report ID: GMI6581
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Organ Transplant Rejection Medication Market Share

The key players in the organ transplant rejection medicine market are

Astellas Pharma Inc.
Sanofi
Bristol-Myers Squibb Company
Novartis AG
F. Hoffmann-La Roche Ltd
Accord Healthcare Ltd
Viatris, Inc.
Dr. Reddy's Laboratories Ltd
Veloxis Pharmaceuticals A/S
GlaxoSmithKline plc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global organ transplant rejection medication industry was valued at USD 5.5 billion in 2022 and is expected to witness growth at CAGR of 3.2% through 2032, driven by organ transplant procedures due to chronic diseases, and technological advancements in organ transplantation and tissue engineering.

The hospital pharmacies segment held a major market share of 61.6% in 2022 as these pharmacies offer easy and rapid access to such medications for the hospitalized patients.

North America organ transplant rejection medicines industry was valued at USD 2.4 billion in 2022, backed by the advanced healthcare infrastructure, increasing medical expenditure, high prevalence of chronic diseases, and focus on R&D activities.

Astellas Pharma Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Accord Healthcare Ltd, Viatris, Inc., Dr. Reddy's Laboratories Ltd, Veloxis Pharmaceuticals A/S, and GlaxoSmithKline plc.